IPO Profile: China Nuokang Bio-Pharmaceutical Inc.

IPO of Chinese pharma company provides little upside to its VC backers, HBM BioVentures and Sequoia Capital

1 February 2010•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.